Background

Melphalan IV (Mel) distribution has been suspended globally due to manufacturing process difficulties occurring in November 2015. We have been using the combination of Ranimustine/Etoposide/Cytarabine/Cyclophosphamide (M-BEAC) as pretreatment for autologous stem-cell transplantation (ASCT) instead of..

The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Please login